safety of glp 1 receptor agonists Frontiers GLP-1 Receptor Agonists and the
Description
10.1038/ijo.2013.149 76 le RouxC
doi: 10.1007/s13300-018-0524-z 80 Zitman-GalT.EinbinderY.OhanaM.KatzavA.KartawyA.BenchetritS

Sublingual delivery: the future for GLP-1 receptor agonists

The clinical development program of lixisenatide: a once-daily glucagon-like Peptide-1 receptor agonist

1, Extended Data Tables 16 and Supplementary Section 2), with a clear trend of growing relevant literature over the past few years as the use of these medications becomes more widespread and their indications expand far beyond the initial intentions of the manufacturers 223

Holst JJ, Burcelin R, Nathanson E